Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
NCT05853887 · View on ClinicalTrials.gov ↗
Study Summary
This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available prior to starting treatment so that physicians can make molecularly-informed treatment decisions. The second goal is to better understand factors that contribute to whether or not the EHR-nudge implementation is successful.
Conditions Studied
Interventions
- BEHAVIORAL iNUDGE
Study Locations (6)
New Jersey
- Penn Medicine Cherry Hill — Cherry Hill
- Penn Medicine Princeton Health — Plainsboro
- Penn Medicine Washington Township — Sewell
- Penn Medicine Voorhees — Voorhees Township
Pennsylvania
- Penn Medicine Lancaster General Health — Lancaster
- Penn Presbyterian Medical Center — Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05853887
The ClinicalTrials.gov registry entry for NCT05853887 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charu Aggarwal, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Non Small Cell Lung Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention — of which iNUDGE is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05853887 reports 6 study locations spanning 2 distinct geographic areas — top geographies include New Jersey, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05853887 about?
NCT05853887 is a clinical study titled "Liquid Biopsy Based NGS in Newly Diagnosed NSCLC". This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available ...
What is the current status of trial NCT05853887?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 260 participants. The study started on 2023-06-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05853887 study?
This clinical trial studies the following conditions: Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05853887?
The interventions under investigation include: iNUDGE (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05853887?
This trial is sponsored by Charu Aggarwal, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05853887 being conducted?
This trial has 6 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.